Aura Biosciences CEO and leadership

Elisabet De Los Pinos is a Board Member at Aura Biosciences and Founder & CEO at Aura Biosciences and is based in Cambridge, Massachusetts. She has worked as Brand Manager Oncology Business Unit at ELI LILLY & CO. Elisabet works or has worked as Post-Doctoral Fellow at Institute of Cancer Research/The. She studied at Institute of Cancer Research/The between 2000 and 2002, University of London between 2000 and 2002, and Icahn School of Medicine at Mount Sinai between 1999 and 1999.

Julie Feder is the CFO at Aura. Prior to this role, Julie served as Chief Financial Officer at Verastem, where she was responsible for developing the company’s strategic financial plan and overseeing a rapid growth in financing and staff size. Prior to joining Verastem, Ms. Feder spent six years at the Clinton Health Access Initiative, Inc. (CHAI) as Chief Financial Officer. At CHAI, Ms. Feder was responsible for managing a global team across multiple departments. She also developed the global finance strategy and internal audit, treasury, and global payroll functions.Prior to joining CHAI, Ms. Feder spent three years at Genzyme Corporation, as Vice President of Internal Audit and later as Finance Integration Leader. In these roles, she managed the day-to-day operations of Genzyme’s global internal audit function, while leading the Genzyme Global Finance integration following Sanofi’s acquisition of Genzyme. Ms. Feder began her career at Deloitte & Touche LLP, where she was Senior Manager of Audit, Consulting and Enterprise Risk Services. Ms. Feder holds a Bachelor of Science in Accounting from Yeshiva University’s Sy Syms School of Business.

Cadmus Rich is CMO at Aura. Before joining Aura, Cadmus was most recently Vice President of Clinical Development and Medical Affairs at Inotek Pharmaceuticals. He previously held several senior positions at Alcon Laboratories, including overseeing the pipeline strategy and R&D projects for Alcon’s intraocular lens product line, and leading global pharmaceutical clinical trial management. Cadmus was board-certified in Ophthalmology in 2002 after completing his residency at the UNC School of Medicine. He obtained his MBA from Regis University, his Certified Physician Executive certification from the American Association for Physician Leadership and his BA in Psychology from Case Western Reserve University. Cadmus has extensive experience in R&D, having led or participated in nearly 75 development programs including the submission and approval of multiple devices and pharmaceutical products in the U.S., EU, China, Japan and Brazil/Latin America. He has directly led or participated in over 150 clinical trials across multiple ophthalmology and systemic indications as an executive leader, medical director, medical monitor and principal investigator. Cadmus has served on the board of directors of the North Carolina Specialty Hospital and is currently a member of the board of directors of Prevent Blindness, the nation’s longest-acting volunteer eye health and safety organization.

Elisabet De Los Pinos is a Board Member at Aura Biosciences and Founder & CEO at Aura Biosciences and is based in Cambridge, Massachusetts. She has worked as Brand Manager Oncology Business Unit at ELI LILLY & CO. Elisabet works or has worked as Post-Doctoral Fellow at Institute of Cancer Research/The. She studied at Institute of Cancer Research/The between 2000 and 2002, University of London between 2000 and 2002, and Icahn School of Medicine at Mount Sinai between 1999 and 1999.

Elisabet De Los Pinos is a Board Member at Aura Biosciences and Founder & CEO at Aura Biosciences and is based in Cambridge, Massachusetts. She has worked as Brand Manager Oncology Business Unit at ELI LILLY & CO. Elisabet works or has worked as Post-Doctoral Fellow at Institute of Cancer Research/The. She studied at Institute of Cancer Research/The between 2000 and 2002, University of London between 2000 and 2002, and Icahn School of Medicine at Mount Sinai between 1999 and 1999.